Results 131 to 140 of about 867,189 (360)
Advancing Cancer Immunotherapy: From Molecular Mechanisms to Clinical Applications
, 2023 In recent years, cancer immunotherapy research has made remarkable progress, completely transforming the cancer treatment landscape [...
Timothy Starr +2 more
core +1 more source
Molecular Oncology, EarlyView.This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source
Journal for ImmunoTherapy of CancerCancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients.
L. Emens +10 more
semanticscholar +1 more source
Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy
Molecular Oncology, EarlyView.We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen +19 more
wiley +1 more source
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Cellular & Molecular ImmunologyIn the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach for combating cancers, demonstrating remarkable efficacy in relapsed/refractory hematological malignancies in both pediatric and ...
Lei Peng +4 more
semanticscholar +1 more source
Immunotherapy in colorectal cancer: rationale, challenges and potential
Nature reviews: Gastroenterology & hepatology, 2019 Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid cancers, including a subset of colorectal cancers (CRCs). Two programmed cell death 1 (PD1)-blocking
K. Ganesh +6 more
semanticscholar +1 more source
Contemporary Approaches to Immunotherapy of Solid Tumors
In recent years, the arrival of the immunotherapy industry has introduced the possibility of providing transformative, durable, and potentially curative outcomes for various forms of malignancies.
Xenia A. Glukhova +4 more
core +1 more source
Molecular Oncology, EarlyView.High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
Role of dendritic cells in the induction of lymphocyte tolerance
Frontiers in Immunology, 2015 The ability of dendritic cells (DCs) to trigger tolerance or immunity is dictated by the context in which an antigen is encountered. A large body of evidence indicates that antigen presentation by steady-state DCs induces peripheral tolerance through ...
Fabiola eOsorio +4 more
doaj +1 more source
Advances in Immunotherapy for Hepatocellular Carcinoma
, 2023 Immune checkpoint inhibitors (ICIs) aim to induce immune responses against tumors and are less likely to develop drug resistance than molecularly targeted drugs. In addition, they are characterized by a long-lasting antitumor effect.
Satoru Hagiwara +2 more
core +1 more source